ReviewCurrent opinion in rheumatology2018
Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy.
Review in Current opinion in rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic).Arthritis research & therapy · 2021Trial
- Changes in attitudes toward systemic lupus erythematosus and associated factors: a retrospective cross-sectional study from China.Frontiers in immunology · 2026Observational
- Prediction of Lupus Classification Criteria via Generative AI Medical Record Profiling.Biotech (Basel (Switzerland)) · 2025Article
- Outgrowth of Escherichia is susceptible to aggravation of systemic lupus erythematosus.Arthritis research & therapy · 2024Article
- Review
- Disease activity is associated with changes in the innate immune function in patients with systemic lupus erythematosus.Clinical rheumatology · 2024Article
- Research progress of T cell autophagy in autoimmune diseases.Frontiers in immunology · 2024Review
- Effect of 8-Hydroxyguanine DNA Glycosylase 1 on the Function of Immune Cells.Antioxidants (Basel, Switzerland) · 2023Review
- Autophagy pathways in autoimmune diseases.Journal of autoimmunity · 2023Review
- Significant improvement of systemic lupus erythematosus manifestation in children after autologous dendritic cell transfer: a case report and review of literature.Therapeutic advances in vaccines and immunotherapy · 2023Article
- Levels of base excision repair proteins in CD4Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Article
- Lupus Susceptibility Loci Predispose Mice to Clonal Lymphocytic Responses and Myeloid Expansion.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Inositol-Requiring Enzyme 1α-Mediated Synthesis of Monounsaturated Fatty Acids as a Driver of B Cell Differentiation and Lupus-like Autoimmune Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2021Article
- Article
- DNA glycosylase deficiency leads to decreased severity of lupus in the Polb-Y265C mouse model.DNA repair · 2021Article
- Article
- Splicing factor SRSF1 limits IFN-γ production via RhoH and ameliorates experimental nephritis.Rheumatology (Oxford, England) · 2021Article
- Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups.Lupus · 2020Article
- High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus.Annals of the rheumatic diseases · 2020Article
- Splicing factor SRSF1 controls T cell hyperactivity and systemic autoimmunity.The Journal of clinical investigation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
purpose of reviewSystemic lupus erythematosus (SLE) pathogenesis is complex. Aberrancies of immune function that previously were described but not well understood are now becoming better characterized, in part through recognition of monogenic cases of lupus-like disease. RECENT
findingsWe highlight here recent descriptions of metabolic dysfunction, cytokine dysregulation, signaling defects, and DNA damage pathways in SLE. Specifically, we review the effects of signaling abnormalities in mammalian target of rapamycin, Rho kinase, Bruton's tyrosine kinase, and Ras pathways. The importance of DNA damage sensing and repair pathways, and their influence on the overproduction of type I interferon in SLE are also reviewed. SUMMARY: Recent findings in SLE pathogenesis expand on previous understandings of broad immune dysfunction. These findings have clinical applications, as the dysregulated pathways described here can be targeted by existing and preclinical therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.